Abivax S.A. (ABVX)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | PHASE2 | Recruiting | 48 |
| NCT05177835 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | PHASE2 | Active Not Recruiting | 203 |
| NCT06456593 | Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | PHASE2 | Recruiting | 212 |
| NCT07453784 | Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation | PHASE1 | Recruiting | 44 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.